References
- No authors listedEuropean Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS FoundationBr J Ophthalmol2017101613019528559477
- KuwayamaYDE-111 Collaborative Trial GroupPhase III double-masked study of fixed combination tafluprost 0.0015%/timolol 0.5% (DE-111) versus tafluprost 0.0015% alone or given concomitantly with timolol 0.5% in primary open angle glaucoma and ocular hypertensionAtarashii Ganka201330811851194
- KuwayamaYDE-III Collaborative Trial GroupA long-term, open-label study of fixed combination tafluprost 0.0015%/timolol 0.5% (DE-III) in patients with open-angle glaucoma or ocular hypertensionAtarashii Ganka2015321133143
- HolloGHommerALopezAARopoAEfficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredientsJ Ocul Pharmacol Ther201430646847524738883
- UedaKTonouchiAFukanoYAsadaHKawazuKTafluprost 0.0015%/timolol 0.5% combination ophthalmic solution (DE-111 ophthalmic solution) formulation design and intraocular penetration in ratsAtarashii Ganka2013301217611766
- MiyataKAmanoASawaMNishidaTA novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeabilityArch Ophthalmol2003121221537153914609908
- KanamotoTKiuchiYTanitoMComparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surfaceJ Ocul Pharmacol Ther201531315616425710276
- QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther201329438238923231442
- WebersCABeckersHJZeegersMPNuijtsRMHendrikseFSchoutenJSThe intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysisOphthalmology2010117112067207420619459
- InoueKOkayamaRHigaRSawadaHWakamuraMTomitaGOcular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combinationJ Ocul Pharmacol Ther201127658158722011049
- InoueKOkayamaRHigaRWakakuraMTomitaGAssessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combinationClin Ophthalmol2012660761222553420
- InoueKOkayamaRHigaRTomitaGEfficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 monthsClin Ophthalmol201481275127925061275
- InoueKSetogawaAHigaRMoriyamaRWakakuraMTomitaGOcular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogsClin Ophthalmol2012623123522347794
- FuwaMUedaKAkaishiTAdvantages of efficacy and safety of fixed-dose tafluprost/timolol combination over fixed-dose latanoprsot/timolol combinationPLoS One201611e015879727383260